Clinical Trial Update: A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial assessing necitumumab in combination with abemaciclib in non-small cell lung cancer has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Necitumumab (necitumumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | Phase 1 | Status: COMPLETED | Results posted: 2020-07-09